<DOC>
	<DOCNO>NCT00587574</DOCNO>
	<brief_summary>Allogeneic hematopoietic cell transplantation offer high cure rate patient hematological oncological disease . Graft-versus-host disease ( attack donor 's white blood cell patient 's tissue ) serious complication also affect patient 's immune system . Therefore , patient early phase allogeneic cell transplantation high risk severe infectious complication . So far , predictive biomarkers development chronic form graft-versus-host disease available . By analyse serially immune cell population peripheral blood investigate whether certain subset cell associate development chronic graft-versus-host disease . In addition , patient ' immune regeneration evaluate serial analysis peripheral blood immune cell population 3 month 2 year allogeneic cell transplantation .</brief_summary>
	<brief_title>Prospective Phase II Study Assessment Regulatory Immune Cell Populations After Allogeneic HSCT</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Receiving graft either HLAidentical sibling donor HLAmatched unrelated donor Receiving graft HLAmismatched sibling donor HLAmismatched unrelated donor Receiving either bone marrow , peripheral blood stem cell cord blood graft Alive day 100 transplant Age 18 year Signed write informed consent Lymphocytopenia allow immunophenotyping Treatment rituximab HSCT study entry Hepatitis B C , HIV infection Secondary posttransplant malignancy include EBVlymphoproliferative disease Karnofsky score 30 Absence inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>chronic graft-versus-host disease</keyword>
</DOC>